Cardiometabolic Risk Parameters in "Nonfunctioning" Adrenal Incidentalomas: A Systematic Review and Meta-analysis.

We sought to analyze the available literature to evaluate AIx, cIMT, FMD, IR, LVMI, and PWV in patients with NFAI as compared to patients without AI.

我们试图分析现有文献以评估与无AI患者相比，NFAI患者的增强指数（Aix）、颈动脉内膜中层厚度（cIMT）、血流介导扩张（FMD）、胰岛素抵抗（IR）、左心室质量指数（LVMI）和脉搏波速度（PWV）。

Methods

Systematic reviewand meta-analysis.

系统评价和荟萃分析。

We included studies that evaluated the cIMT and IR (primary outcomes) and AIx, FMD, LVMI, and PWV (secondary outcomes) in patients with NFAI vs matched subjects without AI.

我们纳入了评估颈动脉内膜中层厚度（cIMT）和胰岛素抵抗（IR，主要结局指标）以及增强指数（AIx）、血管舒张功能（FMD）、左心室质量指数（LVMI）和脉搏波传导速度（PWV，次要结局指标）的患者与无AI的匹配对照组的研究。

A random-effects model (DerSimonian and Laird) was used to calculate the standardized mean difference and 95% CI for each outcome.

使用随机效应模型（DerSimonian和Laird）计算每个结果的标准平均差异及其95%置信区间。

Results

Among the 24 available studies, 21 studies provided the necessary data (2228 subjects, mean age 53.3 ± 2.9 years, 35% males).

在24项可用研究中，有21项提供了所需数据（2228名受试者，平均年龄53.3±2.9岁，35%为男性）。

Data on cIMT, IR, AIx, FMD, LVMI, and PWV were reported in 12 (1063 subjects), 15 (1745 subjects), 2 (140 subjects), 3 (198 subjects), 3 (201 subjects), and 2 (140 subjects) studies, respectively.

cIMT、IR、AIx、FMD、LVMI和PWV的数据分别在12项（1063名受试者）、15项（1745名受试者）、2项（140名受试者）、3项（198名受试者）、3项（201名受试者）和2项（140名受试者）研究中报告。

Compared with patients without AI, patients with NFAI showed statistically significant differences in cIMT, IR, AIx, FMD, LVMI, and PWV (standardized mean difference and 95% CI: 1.22, 0.87-1.58; 0.51, 0.32-0.69; 0.94, 0.38-1.50; -1.24, -1.84- -0.65; 0.41, 0.04-0.78; 1.03, 0.16-1.89, respectively).

与无AI的患者相比，NFAI患者在cIMT、IR、AIx、FMD、LVMI和PWV方面显示出统计学上的显著差异（标准化平均差异和95%置信区间分别为：1.22，0.87-1.58；0.51，0.32-0.69；0.94，0.38-1.50；-1.24，-1.84- -0.65；0.41，0.04-0.78；1.03，0.16-1.89）。

Conclusions

Based on cIMT, IR, AIx, FMD, LVMI, and PWV levels, patients with NFAI may be at increased cardiovascular risk.

基于颈动脉内膜中层厚度(cIMT)、胰岛素抵抗(IR)、增强指数(AIx)、血管内皮功能(FMD)、左心室质量指数(LVMI)和脉搏波传导速度(PWV)水平，非酒精性脂肪肝炎(NFAI)患者可能面临增加的心血管风险。